Seer | Jotup

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Retrieved on:

Thursday, February 29, 2024

Seer, Nature Communications, SP100, Investment, Chair, Growth, Proteomics, Video game

REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points:

REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on:

Wednesday, February 21, 2024

Seer, Q&A, Proteomics, Conference

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA.

Key Points:

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA.
Seer’s management is scheduled to participate in a fireside chat and Q&A session on Monday, March 4th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
An archived replay will be available on the company’s website following the conference.

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Retrieved on:

Thursday, February 1, 2024

Proteomics, Webcast, Seer

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.

Key Points:

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.
Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio.
An archived replay will be available on the company’s website following the event.

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

Retrieved on:

Thursday, December 21, 2023

Q&A, Conference, Proteomics, Seer

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.

Key Points:

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.
Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 10th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.
A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
An archived replay will be available on the company’s website following the conference.

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on:

Friday, November 10, 2023

Proteomics, Financial Services Forum, Diagnosis, Seer, Digital health

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.

Key Points:

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
Seer’s management is scheduled to present on Thursday, November 16th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.
A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio.
An archived replay will be available on the company’s website following the conference.

MozCon 2024 Unveils Stellar Speaker Lineup to Dive Into the Future of Digital Marketing

Retrieved on:

Wednesday, November 29, 2023

Seattle Convention Center, Livestreaming, Seer, SGE, Orbital Media, SEO, ChatGPT, SEO contest, Mobile phone, Moz

SEATTLE, Nov. 29, 2023 /PRNewswire/ -- Leading SEO and marketing software company, Moz has unveiled the official 2024 dates for their annual conference, as well as the first 15 sought-after speakers who will take the stage. MozCon 2024, the two-day, single-track event, will take place on Monday and Tuesday, June 3 and 4, 2024, and will include a total of 20 of the brightest minds in search who promise to deliver unparalleled insights into the ever-evolving world of digital marketing.

Key Points:

MozCon 2024, the two-day, single-track event, will take place on Monday and Tuesday, June 3 and 4, 2024, and will include a total of 20 of the brightest minds in search who promise to deliver unparalleled insights into the ever-evolving world of digital marketing.
It's an exciting time for marketers and SEOs, and an opportunity to capitalize on these innovations, embrace the unknown, and learn new skills.
Our team continuously strives to elevate the experience and provide real value for our audience," said Joelle Irvine, Director of Brand Marketing at Moz.
"We're delighted to welcome back some of our most beloved MozCon speakers while also creating space for fresh perspectives and voices.

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

Retrieved on:

Wednesday, November 8, 2023

Fintech, Health, Therapy, Deloitte Technology Fast 500, Genomics, SEER, Telecommunications, Seer, Proteome, Proteomics, Biotechnology, Pharmaceutical industry

(NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .

Key Points:

(NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Solution of the Year” in the 2023 BioTech Breakthrough Awards program as well as being named to the 2023 Deloitte Technology Fast 500 .
“We're thrilled to receive accolades from both BioTech Breakthrough and Deloitte, as these awards underscore our unwavering dedication to innovation, collaboration, and our mission to advance our understanding of human health.
Seer also announced today that it ranked 5 on the Deloitte Technology Fast 500, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.

Seer Reports Third Quarter 2023 Financial Results

Retrieved on:

Tuesday, November 7, 2023

FDA, Publication, Seer, Proteomics, Certification, Investment, SP100, Video game, Cryptocurrency

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023.

Key Points:

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023.
Gross profit, inclusive of grant and other revenue, was $2.2 million and gross margin was 52% for the third quarter of 2023.
Net loss was $21.1 million for the third quarter of 2023, as compared to $24.0 million for the corresponding prior year period.
Seer will host a conference call to discuss the third quarter 2023 financial results on Tuesday, November 7, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Seer to Report Third Quarter 2023 Financial Results on November 7, 2023

Retrieved on:

Thursday, October 19, 2023

Seer, Proteomics, Webcast, Communications satellite, Music, Broadcasting

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023.

Key Points:

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023.
Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio.
An archived replay will be available on the company’s website following the event.

World Leaders in Proteomics and Genomics to Convene at the 2nd International Top-Down Proteomics Symposium

Retrieved on:

Wednesday, September 20, 2023

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- The 2nd International Top-Down Proteomics Symposium will bring together world leaders in the fields of proteomics, proteoform biology, cell biology, and genomics to present their latest research findings as well as to discuss future directions for building the bridge from genotype to phenotype. The Symposium is hosted by the Consortium for Top-Down Proteomics together with Northwestern University’s Chemistry of Life Processes Institute and will be held in Chicago, IL October 3-5, 2023.

Key Points:

The Symposium will be held Oct. 3-5, 2023 in Chicago, IL.
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- The 2nd International Top-Down Proteomics Symposium will bring together world leaders in the fields of proteomics, proteoform biology, cell biology, and genomics to present their latest research findings as well as to discuss future directions for building the bridge from genotype to phenotype.
The Symposium is hosted by the Consortium for Top-Down Proteomics together with Northwestern University’s Chemistry of Life Processes Institute and will be held in Chicago, IL October 3-5, 2023.
The Symposium is generously supported by sponsorships from Bruker, Quantum-Si, Sciex, Thermo Fisher Scientific, Nautilus Biotechnology, Glyphic Biotechnologies, PacBio, Seer, Agilent, ZefSci, Covaris, CMP Scientific, and Affinisep.